On November 3, 2021 ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, reported the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021), which will be held November 10-14, 2021, in Washington, DC. Additional meeting information can be found on the SITC (Free SITC Whitepaper) website (Press release, ImmunoGenesis, NOV 3, 2021, View Source [SID1234594287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Posters Related to IMGS-001: PD-L1/PD-L2 Dual-Specific Antibody with Effector Function

Title: Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1
Poster Number: 233
Date: November 12, 2021

Title: Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity
Poster Number: 291
Date: November 12, 2021

Posters Related to IMGS-501: STING Immune Stimulating Antibody Conjugate (STING-ISAC)

Title: High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
Poster Number: 758
Date: November 13, 2021

Title: Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory Glioblastoma models
Poster Number: 763
Date: November 12, 2021

Posters Related to Evofosfamide Hypoxia-Reversal Agent in Combination with Checkpoint Inhibitors

Title: Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege
Poster Number: 622
Date: November 13, 2021

Title: Hypoxia reduction in tandem with anti-angiogenic therapy remodels the PDAC microenvironment and potentiates CD40 agonist therapy
Poster Number: 730
Date: November 13, 2021